/Antisense Oligonucleotides Targeting Ezh2 Splicing And Their Use For Treating Cancer And Kidney Disease
Abstract
The present disclosure relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that promote exon 14 skipping in the EZH2 gene, and their use in the treatment of cancer and other diseases.
Full Text
What is claimed is:
The present disclosure relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that promote exon 14 skipping in the EZH2 gene, and their use in the treatment of cancer and other diseases.
Timeline
Filed
03/27/2026Published
07/23/2026Granted
Not AvailableIPC Codes(3)
C12N 15/113:Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 35/00:Antineoplastic agents
C12N 15/86:Viral vectors